Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
2.645 USD -2.40% Intraday chart for Poseida Therapeutics, Inc. -7.84% -21.28%
May. 02 Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos MT
May. 01 Malin Corp investee signs agreement with Astellas Pharma AN

Evolution of the average Target Price on Poseida Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

77504016.R5WNGYeLUkOuBoLKq-0zHuRRXHZfQyFD4-vii_S_5Ow.IP7LXLHqOBHkY_ul4L5CXdcAOxA7elspmr6T-6SLk7l38_9D6PERLvlx2w~d893b5d40b7861beec685c41d5f9a309

Analyst Recommendations on Poseida Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating MT
HC Wainwright Initiates Poseida Therapeutics With Buy and $15 Price Target MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates Overweight Rating MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating MT
Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target MT
POSEIDA THERAPEUTICS : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating MT
POSEIDA THERAPEUTICS : BTIG Initiates Poseida Therapeutics at Buy Rating With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.645 USD
Average target price
14 USD
Spread / Average Target
+429.30%
High Price Target
20 USD
Spread / Highest target
+656.14%
Low Price Target
10 USD
Spread / Lowest Target
+278.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Poseida Therapeutics, Inc.

Piper Sandler
HC Wainwright
Cantor Fitzgerald
BTIG

Ratings for Poseida Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. Consensus Poseida Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW